Oslo, Norway, April 17th 2009

Photocure ASA will present its first quarter 2009 report on Thursday April 29th  at 17:00 (CET) and representatives from the company will be Kjetil Hestdal, President & CEO and Christian Fekete, CFO.

The presentation will be publicly available at www.photocure.com. It will be possible to follow the presentation through a live webcast.
  
The presentation is scheduled to conclude at app. 17:45 (CET).
Please register your attendance at Photocure ASA by Wednesday April 28th at 14:00 (CET).
Contact person: Grete Faye-Schjøll (e-mail: gfs@photocure.no / phone +47 22 06 22 10 / fax +47 22 06 22 18).

Best regards,

Christian Fekete, CFO

 
Photocure ASA
Hoffsveien 48
0377 Oslo, Norway
Telephone: +47 22 06 22 10
Telefax:  +47 22 06 22 18
www.photocure.com

Photocure ASA is a Norwegian pharmaceutical company listed on Oslo Stock Exchange. The company develops and sells pharmaceuticals and medical devices for the treatment and diagnosis of different types of cancer. The products are based on proprietary photodynamic technologies, targeting specific dermatology and oncology markets.
 
Photocure has currently two pharmaceutical products on the market: Metvix®, for the treatment of sun-damaged skin and certain types of skin cancer, and Hexvix®, for the diagnosis of bladder cancer. In addition, the company has developed a proprietary light source, the Aktilite® lamp, which is used in combination with the Metvix cream. Through worldwide studies, Photocure is continuously testing its products for new indications, and the aim is to develop a pipeline of follow-on products and technologies.
 
Photocure®, Metvix®, Hexvix® and Aktilite® are registered trademarks of Photocure ASA.